Lupin is introducing potassium chloride for oral solution in a dosage strength of 20 mEq. The company's product had previously been approved by the Food and Drug Administration.
Lupin's product is the generic of Pharma Research Software Solutions’ potassium chloride for oral solution 20 mEq. It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
The product had a market value of approximately $90 million, according to IQVIA data from September 2019.